United States: Drugs intended for diabetes management and weight loss treatments demonstrate the potential to halt or reverse serious liver disease, according to a new research study.
Semaglutide May Combat Serious Liver Damage
According to research conducted globally under the leadership of a Virginia Commonwealth University researcher, semaglutide, revealed under brand names Ozempic and Wegovy, shows promise in combating metabolic dysfunction-associated steatohepatitis or MASH liver disease while managing associated risk factors, as reported by The Hills.
Liver damage from MASH becomes apparent through its inflammatory components and tissue scarring which occur when fat builds up inside the liver. The Cleveland Clinic reports MASH affects 20 percent of U.S. adults with links to high blood pressure and Type 2 diabetes risk factors.
